Nusinersen Intrathecal Injection Suppliers & Bulk Manufacturers
Available Forms: Intrathecal Injection
Available Strengths: 12 mg/5ml
Reference Brands: Spinraza(US)
Category:
Orphan Drugs
Nusinersen is an antisense oligonucleotide that enhances the production of survival motor neuron protein by modifying RNA splicing. It effectively treats spinal muscular atrophy (SMA), improving muscle strength, motor function, and survival. Benefits include increased mobility, reduced ventilator dependence, and enhanced quality of life for SMA patients.
Nusinersen Intrathecal Injection is available in Intrathecal Injection
and strengths such as 12 mg/5ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nusinersen Intrathecal Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nusinersen Intrathecal Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nusinersen, marketed as Spinraza, is approved in the US by the FDA and in the EU via EMA for spinal muscular atrophy (SMA). Regulatory approval requires a comprehensive dossier including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and worldwide availability, helping SMA patients globally access life-saving treatment and improve quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing